Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Alkermes (NASDAQ:ALKS), a $5.3 billion biopharmaceutical company with a "GREAT" financial health rating according to InvestingPro, saw its Executive Vice President of Research and Development and Chief Medical Officer Craig C. Hopkinson sell 9,000 shares of company stock on October 15, 2025, at prices ranging from $31.51 to $31.60, for a total value of $283,776. The company’s stock, currently trading at $32.23, appears slightly undervalued based on InvestingPro’s Fair Value analysis.
On the same day, Hopkinson also exercised options to acquire 5,000 ordinary shares at a price of $19.34, for a total value of $96,700.
Following the sale, Hopkinson directly owns 73,740 shares of Alkermes. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2025.
In other recent news, Alkermes Plc reported a strong performance for the second quarter of 2025, with total revenues reaching $390.7 million. The company’s proprietary product net sales increased by 14% year-over-year, amounting to $307.2 million. Despite a slight decline in its stock price, Alkermes remains optimistic about achieving the higher end of its financial expectations for the year. This optimism is fueled by strong sales of proprietary products and promising developments in its narcolepsy treatment pipeline. The company’s financial results and future outlook have been a focal point for investors and analysts alike. These recent developments underscore Alkermes’ continued focus on growth and innovation in its product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.